Suvretta’s Prescription for Growth

The firm’s Averill biotech and healthcare funds are now double the size of its flagship funds.

art_suvretta070523.jpg

Illustration by II

It looks like the tail is wagging the dog these days at Aaron Cowen’s Suvretta Capital Management.

The firm’s main funds, Suvretta Partners and Suvretta Offshore Fund, are up about 5 percent this year through June, according to an investor. That’s roughly a third of the return posted by the S&P 500.

Suvretta’s

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Related